Click here for a PDF copy of Hexima’s Annual Financial Report for the year ended June 30 2017.
- Hexima completes enrolment for dose escalation stage of phase 1/2a clinical trial of HXP124 as a novel topical treatment for fungal nail infections
- Hexima Limited – Interim Financial Report for the 6 Months ended 31 December 2017
- Hexima doses first patient in phase 1/2a trial of HXP124 as a novel topical treatment for fungal nail infections
- Recruiting patients for fungal nail study
- VIDEO: CSO Marilyn Anderson interviewed by the AAS.